NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis → What Nvidia insiders don’t want you to know (From Behind the Markets) (Ad) Free HEPA Stock Alerts $1.08 -0.01 (-0.92%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.1550-Day Range$1.08▼$2.6452-Week Range$1.06▼$12.88Volume22,956 shsAverage Volume62,533 shsMarket Capitalization$5.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Hepion Pharmaceuticals alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Read More HEPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEPA Stock News HeadlinesMay 21, 2024 | investorplace.comHEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024April 28, 2024 | nytimes.comU.S. Lags Behind Other Countries in Hepatitis-C TreatmentApril 22, 2024 | finance.yahoo.comWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 21, 2024 | stockhouse.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 20, 2024 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 19, 2024 | marketwatch.comHepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource ConstraintsApril 19, 2024 | marketwatch.comHepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down TrialApril 19, 2024 | finance.yahoo.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialApril 19, 2024 | globenewswire.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' TrialApril 17, 2024 | msn.comHEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023April 14, 2024 | morningstar.comHepion Pharmaceuticals Inc HEPAMarch 24, 2024 | investing.comHepion Pharmaceuticals Inc (HEPA)March 6, 2024 | globenewswire.comHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellFebruary 16, 2024 | finance.yahoo.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsFebruary 16, 2024 | globenewswire.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsJanuary 3, 2024 | finance.yahoo.comHepion Pharmaceuticals to Present at NASH-TAG 2024December 7, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesDecember 7, 2023 | realmoney.thestreet.comHepion Pharmaceuticals downgraded to Hold from Buy at BrooklineDecember 7, 2023 | marketwatch.comHepion Sets Restructuring; To Explore Strategic OptionsDecember 7, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNovember 28, 2023 | finance.yahoo.comHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNovember 28, 2023 | msn.comHepion Pharmaceuticals says Wijngaard buys 5K shares in coNovember 13, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseSee More Headlines Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today6/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HEPA CUSIPN/A CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees22Year Founded2013Profitability EPS (Most Recent Fiscal Year)($9.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-304.79% Return on Assets-161.20% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.85Miscellaneous Outstanding Shares5,470,000Free Float5,366,000Market Cap$6.02 million OptionableNo Data Beta1.70 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Comp: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical DirectorKey CompetitorsImunonNASDAQ:CLSNRenovoRxNASDAQ:RNXTLisata TherapeuticsNASDAQ:LSTAAptorum GroupNASDAQ:APMAprea TherapeuticsNASDAQ:APREView All CompetitorsInsidersPeter WijngaardBought 2,500 shares on 11/27/2023Total: $7,625.00 ($3.05/share)Peter WijngaardBought 2,500 shares on 11/24/2023Total: $7,725.00 ($3.09/share)Peter WijngaardBought 1,000 shares on 9/19/2023Total: $5,640.00 ($5.64/share)Robert T FosterBought 1,600 shares on 9/18/2023Total: $8,960.00 ($5.60/share)Peter WijngaardBought 2,000 shares on 9/15/2023Total: $11,200.00 ($5.60/share)View All Insider Transactions HEPA Stock Analysis - Frequently Asked Questions Should I buy or sell Hepion Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares. View HEPA analyst ratings or view top-rated stocks. How have HEPA shares performed in 2024? Hepion Pharmaceuticals' stock was trading at $3.24 on January 1st, 2024. Since then, HEPA stock has decreased by 66.7% and is now trading at $1.08. View the best growth stocks for 2024 here. Are investors shorting Hepion Pharmaceuticals? Hepion Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 32,800 shares, a decline of 48.7% from the April 30th total of 63,900 shares. Based on an average trading volume of 47,100 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.6% of the company's shares are short sold. View Hepion Pharmaceuticals' Short Interest. When is Hepion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our HEPA earnings forecast. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced its earnings results on Tuesday, April, 16th. The company reported ($2.42) earnings per share for the quarter. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals's stock reverse split on the morning of Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV). How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HEPA) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.